-
Why metal prices are soaring to record highs
-
Stocks tepid in thin pre-Christmas trade
-
UN experts slam US blockade on Venezuela
-
Bethlehem celebrates first festive Christmas since Gaza war
-
Set-piece weakness costing Liverpool dear, says Slot
-
Two police killed in explosion in Moscow
-
EU 'strongly condemns' US sanctions against five Europeans
-
Arsenal's Kepa Arrizabalaga eager for more League Cup heroics against Che;sea
-
Thailand-Cambodia border talks proceed after venue row
-
Kosovo, Serbia 'need to normalise' relations: Kosovo PM to AFP
-
Newcastle boss Howe takes no comfort from recent Man Utd record
-
Frank warns squad to be 'grown-up' as Spurs players get Christmas Day off
-
Rome pushes Meta to allow other AIs on WhatsApp
-
Black box recovered from Libyan general's crashed plane
-
Festive lights, security tight for Christmas in Damascus
-
Zelensky reveals US-Ukraine plan to end Russian war, key questions remain
-
El Salvador defends mega-prison key to Trump deportations
-
Stranger Things set for final bow: five things to know
-
Grief, trauma weigh on survivors of catastrophic Hong Kong fire
-
Asian markets mixed after US growth data fuels Wall St record
-
Stokes says England player welfare his main priority
-
Australia's Lyon determined to bounce back after surgery
-
Stokes says England players' welfare his main priority
-
North Korean POWs in Ukraine seeking 'new life' in South
-
Japanese golf star 'Jumbo' Ozaki dies aged 78
-
Johnson, Castle shine as Spurs rout Thunder
-
Thai border clashes hit tourism at Cambodia's Angkor temples
-
From predator to plate: Japan bear crisis sparks culinary craze
-
Asian markets mostly up after US growth fuels Wall St record
-
'Happy milestone': Pakistan's historic brewery cheers export licence
-
Chevron: the only foreign oil company left in Venezuela
-
US denies visas to EU ex-commissioner, four others over tech rules
-
Dynamite Blockchain Delivers Record Q3 2025
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
SMX's Integrated Value Proposition: One System, Many Markets, Compounding Leverage
-
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
-
Alta Copper Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders and Optionholders to be Held on January 26, 2026
-
Pantheon Resources PLC Announces TR-1: Notification of Major Holdings
-
Bridgeline Expands Footprint with Closeout Retailer Choosing HawkSearch for Its On-Site Search Experience and Personalization
-
Koepka leaves LIV Golf: official
-
US slams China policies on chips but will delay tariffs to 2027
-
Arsenal reach League Cup semis with shoot-out win over Palace
-
Contenders Senegal, Nigeria start Cup of Nations campaigns with wins
-
Tunisia ease past Uganda to win Cup of Nations opener
-
S&P 500 surges to record after strong US economic report
-
UK police say no action against Bob Vylan duo over Israel army chant
-
Libya's top military chief killed in plane crash in Turkey
-
Venezuela passes law to jail backers of US oil blockade
-
French parliament passes emergency budget extension
US regulator approves new generic abortion pill, conservatives outraged
US regulators have approved an additional generic version of the abortion pill mifepristone, a normally routine move that nevertheless angered anti-abortion activists.
A number of conservative figures and anti-abortion groups decried the regulatory step, with the institution Students for Life Action calling it "a stain on the Trump presidency."
The drugmaker Evita said on its website the US Food and Drug Administration had this week approved the company's generic tablet, which is currently approved to end pregnancies up to 70 days of gestation.
The medication is used in the majority of abortions in the United States, and also routinely used for managing early miscarriage.
The FDA originally approved mifepristone in 2000, and another generic already exists.
Approvals of additional generics are typically routine.
But Marjorie Dannenfelser, president of the organization Susan B. Anthony Pro-Life America, called the approval "reckless" and "unconscionable" in a statement Thursday.
Senator Josh Hawley, a Republican from Missouri, said on X he had "lost confidence" in FDA leadership while former vice president Mike Pence posted it was "a complete betrayal of the pro-life movement that elected President Trump."
Pence also called for the dismissal of Robert F. Kennedy Jr, Trump's controversial health chief.
The ruckus comes weeks after Kennedy and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying the FDA was conducting a new review of mifepristone's safety.
Abortion rights organizations have dubbed that a blatant attempt to undermine health care access, and a coalition of attorneys general from more than a dozen Democratic-led states vowed to protect availability of the drug.
The American Medical Association has called the prescription drug "exceedingly safe and effective" and said restricting access to mifepristone would "jeopardize public health."
That take echoes the positions of many leading medical institutions.
Mifepristone, which prevents pregnancy progression, is generally used in combination with misoprostol, which empties the uterus.
O.Karlsson--AMWN